ATLANTA, GA--(Marketwire - August 18, 2010) - ALR Technologies Inc. (
BACKGROUND
Two landmark diabetes studies(1) concluded that diabetes treatment through intensive glucose control can delay or possibly even prevent diabetes-related complications. The HeC System has shown to be a platform that can be used for intensive glucose control. A clinical trial using HeC on patients with diabetes shows 1.2% drop in A1C(2). According to the Centers for Disease Control and Prevention, "in general, every percentage point drop in A1C blood test results (e.g., from 8.0% to 7.0%) can reduce the risk of microvascular complications (eye, kidney, and nerve diseases) by 40%"(3).
THE FEATURES OF HeC
Following are the features of the HeC System that makes the platform effective for intensive glucose control:
HeC is a universal platform that accepts data from blood glucose meters made by all the major manufacturers representing about 70% of the blood glucose testing market; including:
Abbott | LifeScan (Johnson & Johnson Co.) | ||
FreeStyle Lite | OneTouch Ultra 2 | ||
FreeStyle Mini | OneTouch Ultramini | ||
FreeStyle Freedom | |||
FreeStyle Freedom Lite | Roche | ||
Precision Xtra | Aviva | ||
Compact Plus | |||
Bayer | |||
Contour | |||
Contour TS | |||
Breeze 2 |
ALRT filed a 510(k) for the HeC System with the FDA on July 23, 2010 and clearance is expected before the end of 2010. HeC is not available for sale in the U.S. pending 510(k) clearance.
About ALR Technologies Inc.
ALRT Health-e-Connect (HeC) System is the principal product of the Company. HeC is a web based application for medical professionals to improve compliance and adherence of care plans of patients in their homes. HeC is programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases. More information on ALR Technologies and its products can be found at http://www.alrt.com.
This release contains certain "forward-looking statements" relating to ALR Technologies' business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words "estimate," "expect," "anticipate," "believe" and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company's quarterly filings with the Securities Exchange Commission.
(1) DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study; National Diabetes Information Clearinghouse (NDIC) A service of the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), NIH; http://diabetes.niddk.nih.gov/dm/pubs/control/
(2) ALR Technologies Inc. Press Release; http://www.marketwire.com/press-release/Clinical-Trial-Using-ALRT-Health-e-Connect-HeC-System-on-Diabetes-Patients-Shows-12-1298411.htm
(3) Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008. (Page 11-12)
Contact Information:
Public Relations:
678-881-0002 Ext. 704
e-mail: